Calidi Biotherapeutics Inc - CLDI STOCK NEWS

Calidi Biotherapeutics (NYSE: CLDI) reported a cash balance of $9.6 million as of December 31, 2024, and announced the termination of its Standby Equity Purchase Agreement (SEPA) with YA II PN, effective January 23, 2025. The company secured significant funding through multiple channels in Q4 2024, including $9.5 million from public offerings, $2.0 million from warrant exercises, and $3.1 million from its ATM facility. In January 2025, an additional public offering raised $4.25 million in gross proceeds.

The company's strengthened financial position led to the termination of the unused SEPA, which had provided the option to sell up to $25 million of common stock over three years. Recent developments include the acceptance of their RTNova platform abstract for presentation at the AACR Annual Meeting and FDA clearance for a Phase 1b/2 trial of CLD-101 for high-grade gliomas, scheduled to begin enrollment in Q1 2025.

Calidi Biotherapeutics (NYSE: CLDI) announced the acceptance of its abstract for presentation at the AACR Annual Meeting in Chicago (April 25-30, 2025). The presentation, titled 'Development of a Systemic Enveloped Virotherapy for Targeting All Metastatic Sites,' will showcase data from their proprietary RTNova systemic platform.

The platform features a novel vaccinia virus strain enveloped with human cell membrane (extracellular enveloped virus or EEV), designed to target distant tumors while avoiding immune system elimination. This technology aims to address treatment challenges in advanced-stage metastatic cancers, particularly when intratumoral administration isn't feasible.

The company also plans to submit additional data about RTNova's lead clinical candidate selection at the ASCO Annual Meeting in June 2025. This development complements Calidi's existing clinical and preclinical work on localized and intratumoral cell-based virotherapies with SNV (SuperNova) and NNV (NeuroNova).

Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotechnology company focused on targeted antitumor virotherapies, has completed its previously announced public offering. The company sold 5,000,000 shares of common stock at $0.85 per share, raising gross proceeds of approximately $4.25 million.

Ladenburg Thalmann & Co. Inc. served as the exclusive placement agent for the offering, which was conducted under an effective Form S-3 registration statement. The final prospectus was filed with the SEC on January 10, 2025, and is available through the SEC's website and Ladenburg Thalmann & Co. Inc.

Calidi Biotherapeutics (NYSE AMERICAN: CLDI) has announced the pricing of its public offering of 5,000,000 shares of common stock at $0.85 per share, expecting to raise gross proceeds of approximately $4.25 million. The offering is expected to close on January 10, 2025, with Ladenburg Thalmann & Co. Inc. acting as exclusive placement agent.

The company plans to use the net proceeds for working capital and general corporate purposes. The offering is being made through a shelf registration statement on Form S-3, which was declared effective by the SEC on October 10, 2024.

Calidi is a clinical-stage biotechnology company developing targeted immunotherapies, with proprietary technology focused on arming the immune system to fight cancer through stem cell-based platforms carrying oncolytic viruses for multiple oncology indications.

Calidi Biotherapeutics (NYSE AMERICAN: CLDI), a clinical-stage biotechnology company focused on targeted immunotherapies, has announced plans for a public offering of common stock and pre-funded warrants. The offering will be conducted through Ladenburg Thalmann & Co. Inc. as the exclusive placement agent.

The company intends to use the proceeds for working capital and general corporate purposes. The securities will be offered through a shelf registration statement on Form S-3 that was declared effective by the SEC on October 10, 2024. The final size, terms, and completion of the offering are subject to market conditions.

A preliminary prospectus supplement and accompanying prospectus will be filed with the SEC, providing detailed information about the offering terms.

Calidi Biotherapeutics presented data at IOVC and SITC conferences showcasing their RTNova™ systemic enveloped virotherapy technology for targeting metastatic lung cancer. The technology utilizes a tumor-selective vaccinia virus engineered to produce extracellular enveloped viruses (EEVs), designed to target multiple metastatic tumor sites while avoiding immune system clearance.

The data demonstrated RTNova's therapeutic potential in an advanced lung metastasis model, both as a monotherapy and as a viral vector for delivering therapeutic payloads. The technology shows promise in killing and transforming tumor microenvironments across multiple sites, potentially offering new treatment options for previously untreatable metastatic diseases.

Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotechnology company focused on targeted antitumor virotherapies, has completed its previously announced public offering of 4,437,869 shares of common stock. The shares were priced at $1.69 per share, generating gross proceeds of approximately $7.5 million. Ladenburg Thalmann & Co. Inc. served as the exclusive placement agent for the offering, which was conducted under an effective Form S-3 registration statement.

Calidi Biotherapeutics (NYSE AMERICAN: CLDI) has announced the pricing of its public offering of 4,437,869 shares of common stock at $1.69 per share, expecting to raise approximately $7.5 million in gross proceeds. The offering is expected to close around November 15, 2024. Ladenburg Thalmann & Co. Inc. is serving as the exclusive placement agent. The company plans to use the net proceeds for working capital, general corporate purposes, and pre-clinical and clinical trials. The offering is being made through a shelf registration statement that was declared effective on October 10, 2024.

Calidi Biotherapeutics (NYSE AMERICAN: CLDI), a clinical-stage biotechnology company, has announced its intention to conduct a public offering of common stock and pre-funded warrants. The offering will be managed by Ladenburg Thalmann & Co. Inc. as the exclusive placement agent. The company plans to use the net proceeds for working capital and general corporate purposes. The securities are being offered through a shelf registration statement that was declared effective on October 10, 2024. The final size, terms, and completion of the offering are subject to market conditions.